Kobo Biotech
add_icon

Kobo Biotech

2.31
-0.12
(-4.94%)
Market Cap
₹- Cr
PE Ratio
-
Volume
56,859.00
Day High - Low
₹2.43 - ₹2.31
52W High-Low
₹4.56 - ₹2.08
hide
Key Fundamentals
Add Ratio
split_icon_default
Market Cap
- Cr
EPS
-
PB Ratio
-
Book Value
-55.79
EBITDA
-
Dividend Yield
- %
Industry
Chemicals
ROE Growth %
-
Debt to Equity
-
Forecast For
Actual

Company News

View All News
Caret
neutral
Kobo Biotech Limited's Committee of Creditors held its sixth meeting and approved several resolutions with high voting margins. The committee approved costs incurred by Resolution Professional Namrata Randeri from the last meeting with 99.12% voting share, authorizing her to operate bank accounts and manage expenses. Professional fees totaling Rs. 95,500 were ratified with 100% approval, including Rs. 15,000 for advocate M.S. Mano Ranjani for re-filing applications against tax departments, Rs. 40,000 for advocate V.S. Sharma Kollapudi for land document procurement, Rs. 80,500 for operational expenses at Solapur factory maintenance, and Rs. 20,000 additional fees for land building valuation updates. The committee also ratified the extension of time until April 15, 2025 for Prospective Resolution Applicants to submit resolution plans with 99.12% approval. All approved costs will be treated as Insolvency Resolution Process costs.
neutral
Kobo Biotech Limited's Committee of Creditors held its fifth meeting and approved several key resolutions with 98.86% voting share. The committee approved a 90-day extension for the Corporate Insolvency Resolution Process from February 13, 2025 to May 14, 2025, requiring an application to be filed with NCLT Hyderabad Bench. Other approvals included ratification of expenses incurred by the Resolution Professional up to January 17, 2025, appointment of advocate M.S. Mano Ranjani with fees of Rs. 35,000-45,000 for filing the extension application, and appointment of a process advisor for evaluation of resolution plans. The committee also approved legal action against Commercial Tax Department Telangana to recover Rs. 1.97 crores from asset auction proceeds and ratified extension of time for Prospective Resolution Applicants to submit resolution plans until February 8, 2025. Namrata Randeri serves as the Resolution Professional authorized to operate bank accounts and execute these resolutions.
neutral
Kobo Biotech Limited's Committee of Creditors (CoC) held multiple meetings between July and October 2025, making several key decisions during the Corporate Insolvency Resolution Process. In the Thirteenth Meeting (August 4, 2025), the CoC unanimously approved a 21-day extension for the successful resolution applicant to submit Performance Bank Guarantee from July 29, 2025, along with Resolution Professional fees of 1.5% of secured financial creditor payouts. The Twelfth Meeting (July 4, 2025) saw approval of various CIRP costs but rejection of the RP's performance-linked incentive fees. Notably, the CoC approved CVK Technologies Private Limited's resolution plan with 100% voting share while rejecting plans from four other applicants including Resurgent Property Ventures, Sun (Inox) Steels, Beaufond Industries, and Verity Knowledge Solutions. The Fourteenth Meeting (August 25, 2025) approved forfeiture of Rs. 1.05 crore deposited by the previous successful resolution applicant due to non-submission of Performance Bank Guarantee, and sought a 90-day extension beyond 375 days for the CIRP process. The Fifteenth Meeting (October 1, 2025) approved the Request for Resolution Plan and Bid Evaluation Matrix, along with another 90-day extension request beyond 435 days. The CoC also approved inclusion of a Rs. 72.55 lakh claim from Maharashtra GST Department in the creditor list. JM Financial Asset Reconstruction Company Limited holds 99.12% voting share in the committee.
View more
Competitors
LTP
Market Cap (₹ Cr.)
P/E Ratio
Revenue (₹ Cr.)
YoY Revenue Growth %
Net Profit (₹ Cr.)
YoY Profit Growth %
RSI
161.10
-
#1 -
-
-
-
-
41.21
231.68
-
#1 -
-
-
-
-
26.29
477.70
-
#1 -
-
-
-
-
46.25
382.85
-
#1 -
-
-
-
-
35.97
503.45
-
#1 -
-
-
-
-
54.64
73.91
-
#1 -
-
-
-
-
39.19
521.50
-
#1 -
-
-
-
-
31.37
400.10
-
#1 -
-
-
-
-
54.93
189.37
-
#1 -
-
-
-
-
28.08
75.68
-
#1 -
-
-
-
-
39.81
Growth Rate
Revenue Growth
-
Net Income Growth
-
Cash Flow Change
-
ROE
-
ROCE
-
EBITDA Margin (Avg.)
-

Yearly Financial Results

Annual Financials
2015
TTM
Revenue
103
0
Expenses
104
0
EBITDA
-1
0
Operating Profit %
-1 %
0 %
Depreciation
10
0
Interest
24
0
Profit Before Tax
-34
0
Tax
1
0
Net Profit
-35
0
EPS in ₹
-15.47
0.00

Balance Sheet

Balance Sheet
2015
Total Assets
396
Fixed Assets
104
Current Assets
290
Capital Work in Progress
2
Investments
0
Other Assets
290
Total Liabilities
396
Current Liabilities
264
Non Current Liabilities
79
Total Equity
53
Reserve & Surplus
31
Share Capital
23

Cash Flow

Cash Flow
2015
Net Cash Flow
-11
Investing Activities
-5
Operating Activities
7
Financing Activities
-13

Share Holding

% Holding
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Promoter
44.95 %
44.95 %
44.95 %
44.95 %
44.95 %
44.95 %
44.95 %
44.95 %
44.95 %
44.95 %
44.95 %
44.95 %
44.95 %
FIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
DIIs
0.66 %
0.66 %
0.66 %
0.66 %
0.66 %
0.66 %
0.66 %
0.66 %
0.66 %
0.66 %
0.66 %
0.66 %
0.66 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
46.99 %
46.95 %
47.02 %
46.84 %
46.81 %
46.81 %
46.65 %
46.65 %
47.70 %
47.75 %
47.86 %
47.97 %
48.27 %
Others
7.40 %
7.43 %
7.37 %
7.55 %
7.57 %
7.57 %
7.74 %
7.74 %
6.69 %
6.64 %
6.53 %
6.42 %
6.12 %
No of Share Holders
0
5,632
5,611
5,645
5,862
6,064
6,064
6,204
6,496
6,458
6,478
6,530
6,767

Corporate Action

Record Date Corporate Action Information Announcement Day LTP at Annoucement LTP at Record Day
17 Aug 2020 CHANGE OF NAME Change Of Name
NA
17 Aug 2020 0.00 0.00

Announcements

Corporate Insolvency Resolution Process (CIRP)-Outcome of meeting of Committee of CreditorsOct 30, 2025
Corporate Insolvency Resolution Process (CIRP)-Intimation of meeting of Committee of CreditorsOct 30, 2025
Corporate Insolvency Resolution Process (CIRP)-Outcome of meeting of Committee of CreditorsOct 30, 2025
Corporate Insolvency Resolution Process (CIRP)-Intimation of meeting of Committee of CreditorsOct 30, 2025
Corporate Insolvency Resolution Process (CIRP)-Outcome of meeting of Committee of CreditorsOct 30, 2025
Corporate Insolvency Resolution Process (CIRP)-Intimation of meeting of Committee of CreditorsOct 30, 2025
Corporate Insolvency Resolution Process (CIRP)-Outcome of meeting of Committee of CreditorsOct 30, 2025
Corporate Insolvency Resolution Process (CIRP)-Intimation of meeting of Committee of CreditorsOct 30, 2025
Corporate Insolvency Resolution Process (CIRP)-Outcome of meeting of Committee of CreditorsOct 30, 2025
Corporate Insolvency Resolution Process (CIRP)-Intimation of meeting of Committee of CreditorsOct 30, 2025
Corporate Insolvency Resolution Process (CIRP)-Outcome of meeting of Committee of CreditorsOct 30, 2025
Corporate Insolvency Resolution Process (CIRP)-Intimation of meeting of Committee of CreditorsOct 30, 2025
Corporate Insolvency Resolution Process (CIRP)-Outcome of meeting of Committee of CreditorsOct 30, 2025
Corporate Insolvency Resolution Process (CIRP)-Intimation of meeting of Committee of CreditorsOct 30, 2025
Corporate Insolvency Resolution Process (CIRP)-Outcome of meeting of Committee of CreditorsOct 30, 2025
Corporate Insolvency Resolution Process (CIRP)-Intimation of meeting of Committee of CreditorsOct 30, 2025
Corporate Insolvency Resolution Process (CIRP)-Outcome of meeting of Committee of CreditorsOct 30, 2025
Corporate Insolvency Resolution Process (CIRP)-Intimation of meeting of Committee of CreditorsOct 30, 2025
Corporate Insolvency Resolution Process (CIRP)-Outcome of meeting of Committee of CreditorsOct 30, 2025
Corporate Insolvency Resolution Process (CIRP)-Intimation of meeting of Committee of CreditorsOct 30, 2025
Corporate Insolvency Resolution Process (CIRP)-Outcome of meeting of Committee of CreditorsOct 30, 2025
Corporate Insolvency Resolution Process (CIRP)-Intimation of meeting of Committee of CreditorsOct 30, 2025
Corporate Insolvency Resolution Process (CIRP)-Invitation of Resolution PlanOct 16, 2025
Corporate Insolvency Resolution Process (CIRP)-Outcome of meeting of Committee of CreditorsMay 23, 2025
Corporate Insolvency Resolution Process (CIRP)-Intimation of meeting of Committee of CreditorsMay 23, 2025
Corporate Insolvency Resolution Process (CIRP)-Invitation of Resolution PlanFeb 13, 2025
Corporate Insolvency Resolution Process (CIRP)-Outcome of meeting of Committee of CreditorsFeb 13, 2025
Corporate Insolvency Resolution Process (CIRP)-Replacement of Interim Resolution Professional (IRP)Feb 11, 2025
Corporate Insolvency Resolution Process (CIRP)-Intimation of meeting of Committee of CreditorsNov 20, 2024
Corporate Insolvency Resolution Process (CIRP)-List of CreditorsNov 05, 2024
Corporate Insolvency Resolution Process (CIRP)-Public AnnouncementNov 05, 2024
Corporate Insolvency Resolution Process (CIRP)-Appointment of Interim Resolution Professional (IRP)Nov 05, 2024
Corporate Insolvency Resolution Process (CIRP)-Initiation of Corporate Insolvency Resolution Process (CIRP) by Financial CreditorsNov 05, 2024
Corporate Insolvency Resolution Process (CIRP)-Intimation of meeting of Committee of CreditorsOct 10, 2024
Corporate Insolvency Resolution Process (CIRP)-Admission of application by TribunalAug 16, 2024
Unaudited Financial Results For The Quarter Ended 30Th June, 2024.Aug 14, 2024
Board Meeting Intimation for Board Meeting For The Approval Of Unaudited Financial Statement For The Quarter Ended 30Th June, 2024Aug 12, 2024
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018Jul 20, 2024
Announcement under Regulation 30 (LODR)-Resignation of Company Secretary / Compliance OfficerJun 28, 2024
Closure of Trading WindowJun 26, 2024
Stay On The NCLT Order Dated 15Th May, 2024 Of M/S. Arch Pharmalabs Limited (Promoter Entity)May 31, 2024
Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 30, 2024
Announcement under Regulation 30 (LODR)-Resignation of DirectorMay 30, 2024
Audited Financial Results For The Quarter And Year Ended 31St March, 2024.May 30, 2024
Board Meeting Outcome for Submission Of The Audited Financial Results For The Quarter And The Year Ended 31St March, 2024 Along With The Report Of Statutory Auditor Thereon.May 30, 2024
Board Meeting Intimation for Approval Of Financial StatementMay 23, 2024
Admission Of Application Under Section 7 Of Insolvency And Bankruptcy Code, 2016 Against M/S. Arch Pharmalabs Limited (Promoter Entity)May 17, 2024
Compliance Certificate Under Regulation 7(3)Apr 26, 2024
Certificate Pursuant To Regulation 40(9) Of SEBI LODRApr 20, 2024
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018Apr 20, 2024

Technical Indicators